Related Experiment Videos
In vitro cytotoxicity of S16020-2, a new olivacine derivative
S Léonce1, V Perez, M R Casabianca-Pignede
1Division de Cancérologie Expérimentale, Institut de Recherches Servier, Suresnes, France.
Abstract:
S16020-2 is a new olivacine derivative which has recently shown a marked antitumor activity in various experimental models. This study was undertaken in order to measure the inhibition of the proliferation of various sensitive and resistant tumor cell lines, by S16020-2, and to obtain information concerning its mechanism of action. For a continuous exposure, S16020-2 was as cytotoxic as adriamycin (ADR) (mean IC50 of about 28 nM) and on average, 46 fold more potent than elliptinium acetate (ELP), against a panel of 20 non-multidrug resistant cell lines. With a short exposure (1 hour) followed by a post-incubation of 95 hours in drug-free medium, S16020-2 was 5 and 6 fold more cytotoxic than ADR for human lung A549 and murine melanoma B16 cells, respectively. Furthermore, S16020-2 inhibited more actively the formation of colonies issued from proliferating cells, compared to colonies issued from quiescent A549 cells. Because quiescent cells demonstrated a 3 fold lower level of topoisomerase II alpha (topo II) than proliferating cells, these results suggest that this enzyme could be a potential target for S16020-2. In addition, as demonstrated by flow cytometric studies, S16020-2 intercalated into DNA and induced a cell cycle arrest in G2. Cell lines displaying the multidrug resistance (MDR) phenotype, P388/ADR-1, P388/ADR, P388/VCR-20, KB-A1, DC-3F/AD, S1/tMDR, and Colo320DM, were more sensitive to S16020-2 than to ADR or ELP, as shown by the mean resistance factors, 8, 201, and 23 respectively. In addition, the two cell lines displaying the pure classical MDR phenotype, linked exclusively to the P-glycoprotein (P-gp) overexpression (P388/VCR-20 and S1/tMDR), were as sensitive to S16020-2 as their sensitive parental counterparts, although they were resistant to ADR. S16020-2 is thus one of the most potent olivacine and ellipticine derivative yet characterized. The good cytotoxicity of S16020-2 against cells displaying a P-gp-mediated multidrug resistance, and its antitumor activity in vivo delineate an important chemotherapeutic potential for this drug.
Insights
S16020-2, a novel olivacine derivative, shows potent antitumor activity, effectively inhibiting cancer cell proliferation and colony formation. It demonstrates significant cytotoxicity against multidrug-resistant cell lines, suggesting a promising chemotherapeutic potential.
Area of Science:
- Pharmacology and Experimental Therapeutics
- Cancer Biology
- Medicinal Chemistry
Background:
- Olivacine derivatives are being explored for their antitumor properties.
- S16020-2 is a newly synthesized olivacine derivative with demonstrated antitumor activity.
- Understanding its mechanism of action and efficacy against resistant cell lines is crucial.
Purpose of the Study:
- To evaluate the antiproliferative effects of S16020-2 on various tumor cell lines, including drug-sensitive and resistant ones.
- To investigate the mechanism of action of S16020-2.
- To compare its efficacy with established chemotherapeutic agents like adriamycin (ADR) and elliptinium acetate (ELP).
Main Methods:
- Cytotoxicity assays (IC50 determination) were performed on a panel of 20 non-multidrug resistant cell lines.
- Short-term drug exposure followed by post-incubation was used to assess cytotoxicity.
- Colony formation assays were conducted on proliferating and quiescent cells.
- Flow cytometry was employed to study DNA intercalation and cell cycle effects.
- Multidrug resistant (MDR) cell lines, including those with P-glycoprotein (P-gp) overexpression, were utilized.
Main Results:
- S16020-2 exhibited potent cytotoxicity, with a mean IC50 of approximately 28 nM against non-MDR cell lines, comparable to ADR and significantly more potent than ELP.
- Short exposure to S16020-2 was highly cytotoxic to A549 lung and B16 melanoma cells.
- S16020-2 more effectively inhibited colony formation in proliferating cells than in quiescent cells, suggesting topoisomerase II alpha (topo II) as a potential target.
- Flow cytometry indicated DNA intercalation and G2 cell cycle arrest.
- S16020-2 demonstrated greater sensitivity in MDR cell lines compared to ADR and ELP, notably against P-gp-mediated MDR lines.
Conclusions:
- S16020-2 is a highly potent olivacine derivative with significant antitumor activity.
- Its efficacy against P-gp-mediated multidrug-resistant cells highlights its potential as a chemotherapeutic agent.
- The drug's ability to intercalate DNA and induce G2 arrest, along with its activity against resistant cell lines, warrants further clinical investigation.